Dijkshoorn Bas, Raadsen Reinder, Nurmohamed Michael T
Amsterdam Rheumatology and Immunology Center, Location Reade, Department of Rheumatology, Dr. Jan van Breemenstraat 2, 1056 AB Amsterdam, The Netherlands.
Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam University Medical Centers, 1007 MB Amsterdam, The Netherlands.
J Clin Med. 2022 May 11;11(10):2704. doi: 10.3390/jcm11102704.
The risk for developing cardiovascular diseases (CVD) in rheumatoid arthritis (RA) patients is 1.5 times higher compared to the general population. This risk is partly due to the contribution of systemic inflammation in increased atherogenesis, while an increased prevalence of "traditional" cardiovascular risk factors, such as hypertension and dyslipidemia, is also attributed to nearly 50% of the total CVD risk. Most anti-rheumatic medication partly reduces this CVD risk, primarily by reducing inflammation. The increased risk is recognized by most guidelines, which advise consequent screening and multiplying calculated risk scores by 1.5. However, screening in daily clinical practice is poorly done, and RA patients often have undiagnosed and untreated risk factors. In conclusion, even nowadays, RA patients still have an increased risk of developing CVD. Advances in anti-inflammatory treatment partly mitigate this risk, but RA patients need mandatory screening for CV risk factors to turn their CVD risk towards that of the general population.
类风湿关节炎(RA)患者发生心血管疾病(CVD)的风险比普通人群高1.5倍。这种风险部分归因于全身炎症对动脉粥样硬化形成增加的作用,而“传统”心血管危险因素(如高血压和血脂异常)的患病率增加也占CVD总风险的近50%。大多数抗风湿药物部分降低了这种CVD风险,主要是通过减轻炎症。大多数指南都认识到了这种增加的风险,建议进行相应的筛查,并将计算出的风险评分乘以1.5。然而,日常临床实践中的筛查做得很差,RA患者往往有未被诊断和未治疗的危险因素。总之,即使在如今,RA患者发生CVD的风险仍然增加。抗炎治疗的进展部分降低了这种风险,但RA患者需要强制性筛查心血管危险因素,以使他们的CVD风险接近普通人群。